The stent, produced by Fort Worth, Texas-based Alcon, is a micro-invasive surgical device used to reduce intraocular pressure in patients with mild to moderate primary open-angle glaucoma.
A surgeon implants the stent under the surface of the eye, allowing the device to drain excess fluid from the eye to reduce intraocular pressure.
The FDA based its approval on positive results from a two-year study of the stent that included more than 500 glaucoma patients. About 73 percent of patients treated with the CyPass Micro-Stent showed a statistically significant decrease in intraocular pressure.
More articles on medical devices:
Medline to open new distribution center in Fla.
FDA updates recommendations for device modification protocols
FDA approves new Zika genetic test for emergency use
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
